EU Recommends Approval of Fixed-Duration Calquence Regimen for Untreated Chronic Lymphocytic Leukaemia

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has ...

May 01, 2025 | Thursday | News
Addex Therapeutics and Sinntaxis Partner to Advance Dipraglurant for Brain Injury Recovery

Addex Therapeutics  a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neu...

May 01, 2025 | Thursday | News
Rising IgA Nephropathy Cases Drive Demand for Innovative Treatments as Targeted Therapies Gain Ground

IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small blood vessels. It is caused by ...

April 29, 2025 | Tuesday | News
Merck Makes $3.9 Billion Bet on Rare Tumors With SpringWorks Therapeutics Acquisition

  Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $...

April 29, 2025 | Tuesday | News
Debiopharm and Oncodesign Services Partner to Advance Preclinical Radioimmunotherapy Using AbYlink™ Bioconjugation Technology

Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), a Swiss-based global biopharmaceutical company aiming to cure cancer an...

April 28, 2025 | Monday | News
Jazz Pharmaceuticals’ Zanidatamab Receives Positive CHMP Opinion for HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adop...

April 28, 2025 | Monday | News
Argent BioPharma Enters German Market with CannEpil® and CogniCann® Following Regulatory Approval

Argent BioPharma Ltd. , a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into th...

April 24, 2025 | Thursday | News
Boehringer Ingelheim and Tessellate Bio Forge €500M Deal to Develop First-in-Class Oral Cancer Therapies Targeting ALT-Dependent Tumors

Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...

April 23, 2025 | Wednesday | News
Capricorn Scientific and florabio Partner to Advance Animal-Free, High-Yield Cell Culture Solutions

Animal-free, high-yield solutions for scalable production Strategic partnership accelerating innovation from lab to GMP scale Breakthrough media for ...

April 21, 2025 | Monday | News
Eisai and Biogen’s Leqembi® Becomes First Alzheimer’s Therapy Approved in EU to Target Disease Pathology

Eisai Co., Ltd. and Biogen Inc. announced that the European Commission (EC) has granted marketing authorization (MA) for Leqembi® (lecanemab), a m...

April 17, 2025 | Thursday | News
Atelerix Partners with MineBio to Launch Cryo-Free Cell Preservation Technology in China

Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic pres...

April 16, 2025 | Wednesday | News
Lecanemab Becomes First Approved Disease-Modifying Therapy for Early Alzheimer’s in the EU

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild de...

April 16, 2025 | Wednesday | News
Meribel Pharma Solutions Launches as Mid-Size European CDMO with 13 Sites Across France, Spain, and Sweden

A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions has launched today with an extensive integrated network ...

April 15, 2025 | Tuesday | News
Boehringer Ingelheim and Cue Biopharma Partner to Advance First-in-Class B Cell Depletion Therapy for Autoimmune Diseases

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...

April 15, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close